Substitution of ethanol with specially designed microspheres in a TASH procedure Latsios G, Gerckens U, Mueller R, Grube E February 21, 2011
Long-term follow-up (four years) of unprotected left main coronary artery disease treated with paclitaxel-eluting stents (from the TRUE Registry) Godino C, Parodi G, Furuichi S, Latib A, Barbagallo R, Göktekin Ö, Cera M, Mueller R, Tamburino C, Grube E, Di Mario C, Reimers B, Chieffo A, Antoniucci D, Colombo A, Sangiorgi G April 12, 2010
One year results of a new in situ length-adjustable stent platform with a biodegradable Biolimus A9 eluting polymer: results of the CUSTOM-II trial Stella P, Mueller R, Pavlakis G, De Bruyne B, Hauptmann K-E, Morice M, Chevalier B, Fajadet J, Sievert H, Grube E August 20, 2008
Novel drug eluting stent system for customised treatment of coronary lesions: CUSTOM I feasibility trial 24 month results Grube E, Sievert H, Hauptmann K-E, Mueller R, Gerckens U, Buellesfeld L, Ako J, Shimohama T, Costa M, Fitzgerald P May 13, 2008
Local intra-renal fenoldopam infusion causes greater increases in renal artery flow velocity than systemic intravenous fenoldopam infusion: a pilot study Grube E, Baim D, Burkhoff D, Mueller R, Buellesfeld L, Teirstein P November 20, 2005
New Issue TAVI dysfunction, coronary sinus narrowing, carotid interventions through the snuffbox, and more CT image showing a case of valve thrombosis after ViV TAVI February 20, 2020
JAA This Weeks JAA's: SAFE-A study, Coronary access after TAVR-in-TAVR and much more February 25, 2020
Trials Book New Update: CULPRIT, NOBEL, IVUS-XPL, SAFARI-STEMI (supported by Biotronik) February 14, 2020